JSPR
Jasper Therapeutics, Inc.Company Information
- Company Name
- Jasper Therapeutics, Inc.
- CIK
- CIK0001788028
- Category
- <br>Emerging growth company
- Ticker: Exchange
- JSPR: Nasdaq, JSPRW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- JSPR
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-09-22
- Last sale
- 2024-12-12
- Shares purchased (TTM)
- 143,000
- Shares sold (TTM)
- 900
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 11,457,155
- Shares outstanding
- 28,696,937
- Ownership
- 39.92%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -10.25%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 7 | 14 | 29 | 51 | 40 | 49 | 72 | 93 | 107 | 118 | 87 | 104 | ||||||
| Restricted Cash Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 4 | 6 | 6 | 4 | 3 | 4 | 4 | 2 | 2 | 2 | 2 | 1 | ||||||
| Assets Current | 12 | 20 | 35 | 55 | 43 | 53 | 76 | 95 | 109 | 120 | 89 | 105 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Restricted Cash Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Assets | 12 | 21 | 36 | 57 | 46 | 58 | 80 | 99 | 114 | 126 | 95 | 110 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 6 | 9 | 8 | 3 | 4 | 3 | 3 | 2 | 4 | 3 | ||||||
| Operating Lease Liability Current | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 5 | 6 | 6 | 10 | 11 | 8 | 10 | 8 | 6 | 6 | 7 | 8 | ||||||
| Liabilities Current | 8 | 9 | 13 | 21 | 21 | 12 | 15 | 12 | 10 | 9 | 12 | 12 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Warrants And Rights Outstanding | 3 | 7 | 16 | 23 | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | - | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 10 | 18 | 32 | 46 | 23 | 15 | 18 | 16 | 14 | 13 | 16 | 16 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 322 | 321 | 321 | 319 | 312 | 304 | 303 | 300 | 298 | 297 | 248 | 247 | ||||||
| Retained Earnings Accumulated Deficit | -321 | -318 | -317 | -308 | -289 | -262 | -241 | -217 | -198 | -183 | -170 | -153 | ||||||
| Stockholders Equity | 1 | 3 | 4 | 12 | 24 | 42 | 62 | 84 | 100 | 113 | 78 | 94 | ||||||
| Liabilities And Stockholders Equity | 12 | 21 | 36 | 57 | 46 | 58 | 80 | 99 | 114 | 126 | 95 | 110 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 492 | 492 | 492 | 492 | 492 | 492 | 492 | 492 | 492 | 492 | 492 | 492 | ||||||
| Common Stock Shares Issued | 28 | 28 | 28 | 28 | 16 | 15 | 15 | 15 | 15 | 15 | 11 | 11 | ||||||
| Shares Outstanding | 28 | 28 | 28 | 28 | 16 | 15 | 15 | 15 | 15 | 15 | 11 | 11 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJasper Therapeutics, Inc. (JSPR) — SEC Financial Statements & Analysis
Jasper Therapeutics, Inc. (JSPR) is a biological products, (no diagnostic substances) company, incorporated in DE. Jasper Therapeutics, Inc. trades on Nasdaq as: JSPR, JSPRW. Jasper Therapeutics, Inc. (JSPR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Jasper Therapeutics, Inc. carries a market cap of $12.08M, a P/E ratio of -0.38x, a P/B ratio of 8.55x, an enterprise value of $4.35M, and an EV/EBITDA multiple of -0.08x. On profitability, it posts a Return on Equity (ROE) of -255.05% and a Return on Assets (ROA) of -109.05%. Per share, it reports EPS of $-1.11, diluted EPS of $-1.11, free cash flow per share of $-2.10, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -65.06% year-over-year and EPS growth of -81.33% year-over-year. On the balance sheet, it maintains a current ratio of 1.47x, a quick ratio of 0.99x, working capital of $3.73M, a debt-to-equity ratio of 7.35x, a debt ratio of 0.88, an interest coverage ratio of -582.03x, free cash flow of $-60.33M (TTM), and net debt of $-7.73M. Figures sourced from SEC EDGAR.
- Market Cap
- $12.08M
- P/E TTM
- -0.38x
- EPS TTM
- $-1.11
- P/B TTM
- 8.55x
- ROE TTM
- -255.05%
- ROA TTM
- -109.05%
- Debt To Equity
- 7.35x
- Free Cash Flow TTM
- $-60.33M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Jasper Therapeutics, Inc. in?
Jasper Therapeutics, Inc. (JSPR) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does JSPR trade on?
Jasper Therapeutics, Inc. (JSPR) trades on the Nasdaq.
Where is Jasper Therapeutics, Inc. incorporated?
Jasper Therapeutics, Inc. is incorporated in DE.
When was Jasper Therapeutics, Inc. (JSPR)'s most recent SEC filing?
Jasper Therapeutics, Inc. (JSPR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is JSPR's market cap?
Jasper Therapeutics, Inc. (JSPR) has a market capitalization of $12.08M as of 2026-06-30.
What is JSPR's EPS (earnings per share)?
Jasper Therapeutics, Inc. (JSPR)'s trailing twelve month EPS is $-1.11 as of 2026-06-30.
What is JSPR's ROE (return on equity)?
Jasper Therapeutics, Inc. (JSPR)'s trailing twelve month Return on Equity (ROE) is -255.05% as of 2026-06-30.
What is JSPR's ROA (return on assets)?
Jasper Therapeutics, Inc. (JSPR)'s trailing twelve month Return on Assets (ROA) is -109.05% as of 2026-06-30.
What is JSPR's EV/EBITDA?
Jasper Therapeutics, Inc. (JSPR)'s trailing twelve month EV/EBITDA is -0.08x as of 2026-06-30.